ABOUT

Connecting CAR-T Developers

CRITICAL CHALLENGES

CINNAMON addresses the critical challenges limiting widespread access to CAR‑T cell therapies, including infrastructure disparities, high production costs, regulatory complexity, and limited manufacturing capabilities in many European regions.

THE ACTION

The Action promotes a coordinated approach to:

  • Standardising CAR‑T manufacturing and quality control

  • Developing next‑generation CAR‑T therapies

  • Facilitating clinical data sharing

  • Supporting decentralised, point-of-care manufacturing models

  • Increasing public awareness and patient engagement

  • Enhancing training opportunities, especially for inclusiveness target countries (ITCs)

OBJECTIVES

CINNAMON pursues a strategic set of Research Coordination and Capacity‑Building
Objectives. 
 RESEARCH COORDINATION OBJECTIVES:
TO BUILD
the foundation for sustainable collaboration and foster cross-border partnerships that will accelerate the development of CAR-T cell therapies
TO ADOPT
common standards to streamline manufacturing practices, reduce variability and ensure high quality treatments for patients across Europe
T0 ADDRESS
manufacturing bottlenecks, thus expanding the availability of CAR-T therapy and reducing production costs
TO PROMOTE
the joint development of novel CAR-T cell therapies among academic researchers by encouraging the preclinical development of novel products for diverse clinical conditions
TO DEVELOP
common guidelines to facilitate regulatory approvals. This could potentially reduce delays in market authorization, enabling faster patient access to innovative therapies
TO FACILITATE
clinical data sharing and collaborative research among clinicians. This will enhance research capabilities and foster continuous improvements in patients’ care and outcome

CAPACITY-BUILING OBJECTIVES:

  • TO ENHANCE COLLABORATIVE RESEARCH
    infrastructure and resource access, addressing disparities in infrastructure and building a robust network by facilitating resource sharing and technical capacity across European institutions.

  • TO PROMOTE PUBLIC AWARENESS AND PATIENT ENGAGEMENT,
    emphasizing the importance of public/patient involvement in the scientific process, thus promoting trust and ensuring that CAR-T therapies meet societal needs and expectations.
  • TO PROMOTE KNOWLEDGE EXCHANGE AND TRAINING,
    by providing regular opportunities for networking and specialized training, ensuring the workforce remains at the forefront of innovation.
  • TO ENCOURAGE YOUNG RESEARCHES AND INNOVATORS (YRI)
    participation by creating a supportive ecosystem for career development, ensuring long-term growth and innovation in the field.